FDA Approval Generic Pharmaceutical Marketing Sales 
The Pharma Data
MARCH 22, 2023
The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira ® * (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
The Pharma Data
APRIL 4, 2023
The approval includes all indications covered by the reference medicine*: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. Source link: [link]
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 17, 2022
Sandoz’ Hyrimoz 50 mg/mL was first approved by the European Commission in July 2018 and launched in several European countries shortly thereafter. The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL. Our ambition is to be the world’s leading and most valued generics company.
Pharmaceutical Technology
DECEMBER 22, 2022
Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising. The category includes any projects that demonstrate an innovative approach to the market.
XTalks
AUGUST 2, 2023
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. billion in pharmaceutical sales from 2021.
Expert insights. Personalized for you.
40 
Let's personalize your content